No Data
Hualv Biological (300970.SZ): has repurchased a total of 2.3466 million shares.
Galonn announced on November 4th that Hualv Biology (300970.SZ) disclosed that as of October 31, 2024, the company repurchased 2.3466 million shares of the company through the Shenzhen Stock Exchange stock trading system through centralized bidding trading method, accounting for 1.95% of the current total share capital. The highest fill price was 13.83 yuan/share, the lowest fill price was 12.22 yuan/share, and the total fill amount was RMB 30.0046 million (excluding trading fees).
October 29th A-share investment lightning rod │ West Point Pharmaceutical: Shareholders Guotou High-Tech and Hangzhou Chuanghe plan to collectively reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.
Hualu Biotech: Report for the third quarter of 2024
Hualu Biotech: 2024 Semi-Annual Report
Hualu Biotech: Summary of the 2024 Semi-Annual Report
Hualv Biology (300970.SZ): The net loss in the first half of the year was 44.8245 million yuan.
On August 27th, Huasheng Bio (300970.SZ) released its semi-annual report for 2024. During the reporting period, the company's revenue was 0.463 billion yuan, a decrease of 12.45% year-on-year. The net loss attributable to shareholders of the listed company was 44.8245 million yuan, a change from profit to loss. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 45.8423 million yuan, a change from profit to loss. The basic loss per share was 0.3840 yuan/share.
